
Axsome: An Undervalued Biotech Stock With A Short-Term Catalyst (NASDAQ:AXSM)
Dean Mitchell/E+ via Getty Images We believe AXS-07 has a high chance of approval in April 2022 Axsome Therapeutics (NASDAQ:AXSM) has announced that the U.S. FDA accepted the New Drug Application (NDA) filing for AXS-07, […]